Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03906292
Title Frontline Asciminib Combination in Chronic Phase CML (CMLXI)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Jena
Indications

chronic myeloid leukemia

Therapies

Asciminib + Nilotinib

Asciminib + Imatinib

Asciminib + Dasatinib

Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.